PKU Market to Grow at 11% CAGR Through 2032 – Emerging Treatments According to a newly published market research report by 24LifeSciences, global Phenylketonuria (PKU) market was valued at USD 1.35 billion in 2024 and is projected to reach USD 2.77 billion by 2031, growing at a compound annual growth rate (CAGR) of 11.0% during the forecast period 2025–2031. Phenylketonuria (PKU) is a rare inherited metabolic disorder characterized by a deficiency of the enzyme phenylalanine hydroxylase (PAH), which is essential for metabolizing the amino acid phenylalanine. This deficiency leads to a dangerous accumulation of phenylalanine in the blood, which, if left untreated, can cause severe and irreversible neurological damage, intellectual disability, seizures, and behavioral issues. Lifelong management through a strict phenylalanine-restricted diet remains the foundation of treatment, though pharmaceutical options have expanded significantly in recent years. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/6724/phenylketonuria-pku-market-market